Dalbavancin exposure in vitro selects for dalbavancin-nonsusceptible and vancomycin-intermediate strains of Methicillin-Resistant Staphylococcus aureus

OBJECTIVES: Dalbavancin is a lipoglycopeptide active against methicillin-resistant Staphylococcus aureus (MRSA). Its long half-life (8.5–16 days) allows for once-weekly or single-dose treatments but could prolong the mutant selection window, promoting resistance and cross-resistance to related antim...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Microbiol Infect
Main Authors: Werth, Brian J., Ashford, Nathaniel, Penewit, Kelsi, Waalkes, Adam, Holmes, Elizabeth A., Ross, Dylan H., Shen, Tianwei, Hines, Kelly M., Salipante, Stephen J., Xu, Libin
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7914275/
https://ncbi.nlm.nih.gov/pubmed/32866650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cmi.2020.08.025
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki